Sunday, 26 September 2021


Aurobindo recalls epilepsy drug lot in US

25 November 2014 | Regulatory | By BioSpectrum Bureau

Aurobindo recalls epilepsy drug lot in US

Aurobindo Pharma in the US is recalling Gabapentin drug lot for containing empty capsules

Aurobindo Pharma in the US is recalling Gabapentin drug lot for containing empty capsules

Singapore: India-based Aurobindo Pharma in the US is recalling Gabapentin capsules, USP 300 mg 100-count bottles, at consumer level due to possible stashs of some empty capsules.

USFDA has advised that empty capsules could result in missed dose(s) of gabapentin resulting in adverse health consequences that could range from no effect, short term reduction in efficacy, short term withdrawal effect, or status epilepticus (long period seizures) that could be life-threatening.

Gabapentin is used as in the treatment of epilepsy and for the management of postherpetic neuralgia (pain after shingles).

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account